No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.

• Wuhan Hiteck Biological Pharma Co.,Ltd
• ScinoPharm Taiwan, Ltd.
• Bliss GVS Pharma Limited
• Evolus, Inc.
• Orchid Pharma Limited
• Synmosa Biopharma Corporation
• Tilray Brands, Inc.
• Shaanxi Kanghui Pharmaceutical Co., Ltd.